A Study to Evaluate the Effect of Lorcaserin Hydrochloride on Smoking Cessation

Summary

In smokers who are motivated to stop smoking, treatment with lorcaserin compared with placebo will provide greater abstinence as measured by the last 4 weeks of treatment (Weeks 9-12). The target quit date was Day 15.

Timeline

Start

2014-03

Primary completion

2014-11

Completion

2014-11

Outcome

Met primary endpoint

registry NUMBER APD356 10 mg b.i.d.: 15.31 percentage of participants NUMBER APD356 10 mg q.d.: 8.72 percentage of participants NUMBER Placebo: 5.64 percentage of participants NCT02044874 ↗

registry analysis (superiority or other test); APD356 10 mg b.i.d. vs Placebo; p = 0.0027; Odds Ratio (OR) 3.02 (95% CI 1.47 to 6.22); Regression, Logistic NCT02044874 ↗

Publications

• Hartmann-Boyce J, Theodoulou A, Farley A, Hajek P, Lycett D, Jones LL, Kudlek L, Heath L, Hajizadeh A, Schenkels M, Aveyard P. Interventions for preventing weight gain after smoking cessation. Cochrane Database Syst Rev. 2021 Oct 6;10(10):CD006219. doi: 10.1002/14651858.CD006219.pub4.
• Shanahan WR, Rose JE, Glicklich A, Stubbe S, Sanchez-Kam M. Lorcaserin for Smoking Cessation and Associated Weight Gain: A Randomized 12-Week Clinical Trial. Nicotine Tob Res. 2017 Aug 1;19(8):944-951. doi: 10.1093/ntr/ntw301.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Lorcaserin	Small molecule	10 mg	Oral

Indications

No indication recorded.